Vermont Selects 20/20 Biolabs' Multi-Cancer Test for Firefighter Screening
Event summary
- Vermont will screen up to 4,500 firefighters using 20/20 Biolabs' OneTest™ MCED blood test.
- The 12-month program, in partnership with National Diagnostic Services, is expected to generate ~$500,000 in revenue for 20/20 Biolabs.
- Vermont is the second state to fund firefighter cancer screening with OneTest™, following Maryland's $400,000 reimbursement this quarter.
- The contract is renewable for up to two additional 12-month periods.
- OneTest™ combines protein biomarkers, clinical factors, and AI for early cancer detection.
The big picture
This deal underscores the growing recognition of multi-cancer early detection (MCED) testing for high-risk occupational groups. The strategic anomaly here is the shift from DNA-based tests to protein biomarker-based tests like OneTest™, which are seen as more affordable and effective for early-stage cancer detection. The broader industry trend of AI-powered diagnostics is gaining traction, particularly as governments and insurers seek cost-effective solutions for preventive healthcare.
What we're watching
- Market Expansion
- Whether 20/20 Biolabs can replicate this success in other states, given the elevated cancer risks faced by firefighters nationwide.
- Regulatory Tailwinds
- The impact of the February 2026 Medicare coverage pathway for MCEDs, which could accelerate adoption of OneTest™ beyond firefighter screening.
- Execution Risk
- The pace at which 20/20 Biolabs can scale its testing capacity and data collection to support Medicare reimbursement efforts.
Related topics